AUTHOR=Lin Chien-Yu , Wei Sheng-Huan , Chen Yi-Lin , Lee Chung-Ta , Wu Shang-Yin , Ho Chung-Liang , Pavlick Dean C. , Su Po-Lan , Lin Chien-Chung 

TITLE=Case report: Salvage capmatinib therapy in KIF5B-MET fusion-positive lung adenocarcinoma with resistance to telisotuzumab vedotin

JOURNAL=Frontiers in Oncology

VOLUME=12

YEAR=2022

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.919123

DOI=10.3389/fonc.2022.919123

ISSN=2234-943X

ABSTRACT=<p>Telisotuzumab vedotin is a <italic>MET</italic>-targeting antibody–drug conjugate that has demonstrated a good treatment response in patients with <italic>EGFR</italic> wild-type MET-overexpressing non-squamous non-small cell lung cancer. However, patients have been reported to acquire resistance to this drug, and the subsequent therapy has not been standardized. Here, we present a case of a 56-year-old woman diagnosed with <italic>KIF5B-MET</italic> fusion-positive non-small cell lung cancer who had a durable response to capmatinib after acquired resistance to telisotuzumab vedotin.</p>